Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medicare Rx Means “Dramatic” Change For Pharma; CMS Is New FDA – Scully

Executive Summary

The Medicare drug benefit will make the Centers for Medicare & Medicaid Services at least as important to the pharmaceutical market as FDA, former CMS Administrator Tom Scully predicts

You may also be interested in...



CMS Influence Over Rx Industry Could Change Culture At FDA – Millennium

The increasing influence of the Centers for Medicare & Medicaid Services within the prescription drug industry could create opportunities for a "cultural shift" at FDA, Millennium Senior VP-R&D Strategy and Operations Abie Celniker said

CMS Influence Over Rx Industry Could Change Culture At FDA – Millennium

The increasing influence of the Centers for Medicare & Medicaid Services within the prescription drug industry could create opportunities for a "cultural shift" at FDA, Millennium Senior VP-R&D Strategy and Operations Abie Celniker said

Rx Industry Must Change “Mission” To Prepare For Medicare – Scully

The Medicare prescription drug benefit that begins in 2006 will fundamentally change the mission of pharmaceutical companies, former Centers for Medicare & Medicaid Services Administrator Tom Scully told the Washington Research Group's annual symposium in Washington, D.C. Nov. 5

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS043181

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel